Study of INCA036978 in Participants With Myeloproliferative Neoplasms
Key claim: A Phase 1 study is evaluating the safety, tolerability, dose-limiting toxicities, maximum tolerated dose, and recommended expansion dose of INCA036978 as monotherapy and in combination with standard disease-directed therapy in patients with myeloproliferative neoplasms.
Abstract
This study will be conducted to determine the safety, tolerability, dose-limiting toxicity (DLT)s, and maximum tolerated dose (MTD) and/or recommended dose for expansion (RDE)s of INCA036978 administered as monotherapy and in combination with a standard disease-directed therapy.
Why this matters
INCA036978 enters the MPN investigational pipeline as a Phase 1 first-in-human agent being tested both alone and layered onto standard disease-directed therapy, signaling Incyte’s continued expansion beyond JAK inhibition. Until mechanism-of-action and early PK/PD data are disclosed, its place in the treatment landscape — and whether it competes with or complements ruxolitinib-based backbones — remains undefined. Worth tracking for first dose-escalation readouts that would clarify class and target.